Mechanism of diabetic neuropathy: Where are we now and where to go?

Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines, activation of protein kinase C and exaggerated oxidative stress, as well as other confounding factors. Although these metabolic aberrations are deemed as the main stream for the pathogenesis of diabetic microvascular complications, organ‐specific histological and biochemical characteristics constitute distinct mechanistic processes of neuropathy different from retinopathy or nephropathy. Extremely long axons originating in the small neuronal body are vulnerable on the most distal side as a result of malnutritional axonal support or environmental insults. Sparse vascular supply with impaired autoregulation is likely to cause hypoxic damage in the nerve. Such dual influences exerted by long‐term hyperglycemia are critical for peripheral nerve damage, resulting in distal‐predominant nerve fiber degeneration. More recently, cellular factors derived from the bone marrow also appear to have a strong impact on the development of peripheral nerve pathology. As evident from such complicated processes, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00070.x, 2010)

[1]  S. Chung,et al.  More severe type 2 diabetes‐associated ischemic stroke injury is alleviated in aldose reductase‐deficient mice , 2010, Journal of neuroscience research.

[2]  E. Agardh,et al.  Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. , 2010, International journal of molecular medicine.

[3]  Ravichandran Ramasamy,et al.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. , 2010, Circulation research.

[4]  G. King,et al.  Activation of protein kinase C isoforms and its impact on diabetic complications. , 2010, Circulation research.

[5]  Ashutosh Kumar,et al.  NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. , 2010, Biochemical and biophysical research communications.

[6]  S. Chung,et al.  The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice , 2010, The Journal of pathology.

[7]  G. Alton,et al.  Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. , 2010, Investigative ophthalmology & visual science.

[8]  R. Wada,et al.  Neuropathy induced by exogenously administered advanced glycation end‐products in rats , 2010, Journal of diabetes investigation.

[9]  M. Boulton,et al.  Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock , 2009, The Journal of experimental medicine.

[10]  E. Feldman,et al.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy , 2009, Journal of the peripheral nervous system : JPNS.

[11]  K. Faulkner,et al.  Sensory and Motor Peripheral Nerve Function and Lower‐Extremity Quadriceps Strength: The Health, Aging and Body Composition Study , 2009, Journal of The American Geriatrics Society.

[12]  I. Obrosova Diabetes and the peripheral nerve. , 2009, Biochimica et biophysica acta.

[13]  J. Jakobsen,et al.  Expression of neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength. , 2009, Brain : a journal of neurology.

[14]  E. Agardh,et al.  The Aldose Reductase Inhibitor Fidarestat Suppresses Ischemia-Reperfusion-Induced Inflammatory Response in Rat Retina , 2009, Pharmacology.

[15]  Paul J Thornalley,et al.  Advanced Glycation End Products in Extracellular Matrix Proteins Contribute to the Failure of Sensory Nerve Regeneration in Diabetes , 2009, Diabetes.

[16]  Y. Yoon,et al.  Bone Marrow Mononuclear Cells Have Neurovascular Tropism and Improve Diabetic Neuropathy , 2009, Stem cells.

[17]  C. Sabanayagam,et al.  Relationship between glycated haemoglobin and microvascular complications: Is there a natural cut-off point for the diagnosis of diabetes? , 2009, Diabetologia.

[18]  Thomas E. Lyons,et al.  Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  R. Pop-Busui,et al.  Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort , 2009, Journal of the peripheral nervous system : JPNS.

[20]  P. Fernyhough,et al.  Development of Selective Axonopathy in Adult Sensory Neurons Isolated From Diabetic Rats , 2009, Diabetes.

[21]  Y. Yoon,et al.  Dual Angiogenic and Neurotrophic Effects of Bone Marrow–Derived Endothelial Progenitor Cells on Diabetic Neuropathy , 2009, Circulation.

[22]  R. Pop-Busui,et al.  Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. , 2009, American journal of physiology. Heart and circulatory physiology.

[23]  A. Quattrini,et al.  Diabetes regulates mitochondrial biogenesis and fission in mouse neurons , 2009, Diabetologia.

[24]  T. Asano,et al.  Regulation of Pancreatic β Cell Mass by Neuronal Signals from the Liver , 2008, Science.

[25]  R. Kawamori,et al.  Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[26]  M. Pietropaolo,et al.  Stimulation of autophagy by autoantibody-mediated activation of death receptor cascades , 2008, Autophagy.

[27]  P. Nawroth,et al.  The RAGE Pathway , 2008, Annals of the New York Academy of Sciences.

[28]  W. Liu,et al.  Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy , 2008, Diabetes.

[29]  S. Yagihashi,et al.  Role of advanced glycation end products in diabetic neuropathy. , 2008, Current pharmaceutical design.

[30]  R. Wada,et al.  Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated‐γ‐ligand, in insulin‐deficient diabetic rats , 2007, Journal of neurochemistry.

[31]  Koichi Kato The pathogenesis of diabetic neuropathy , 2008 .

[32]  J. Groves,et al.  Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats. , 2007, American journal of physiology. Endocrinology and metabolism.

[33]  D. Zochodne,et al.  RAGE, diabetes, and the nervous system. , 2007, Current molecular medicine.

[34]  S. Chung,et al.  Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. , 2007, Experimental eye research.

[35]  J. Nadler,et al.  High-Fat Diet–Induced Neuropathy of Pre-Diabetes and Obesity , 2007, Diabetes.

[36]  Soroku Yagihashi,et al.  Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. , 2007, Diabetes research and clinical practice.

[37]  G. Ryan New pharmacologic approaches to treating diabetic retinopathy. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[38]  Nathan Efron,et al.  Surrogate Markers of Small Fiber Damage in Human Diabetic Neuropathy , 2007, Diabetes.

[39]  S. Sharma,et al.  Preventive and curative effect of edaravone on nerve functions and oxidative stress in experimental diabetic neuropathy. , 2007, European journal of pharmacology.

[40]  N. Calcutt,et al.  Pathogenesis of Spinally Mediated Hyperalgesia in Diabetes , 2007, Diabetes.

[41]  M. Mata,et al.  Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer , 2007, Diabetologia.

[42]  R. Dobrowsky,et al.  Neurotrophic modulation of myelinated cutaneous innervation and mechanical sensory loss in diabetic mice , 2007, Neuroscience.

[43]  G. Cavaletti,et al.  Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis , 2007, Neuroscience.

[44]  A. Sastry,et al.  Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. , 2007, Endocrinology.

[45]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[46]  Fei Li,et al.  The Leptin-Deficient (ob/ob) Mouse , 2006, Diabetes.

[47]  E. Feldman,et al.  Mechanisms of Disease: mitochondria as new therapeutic targets in diabetic neuropathy , 2006, Nature Clinical Practice Neurology.

[48]  S. Kusunoki,et al.  Effect of the aldose reductase inhibitor fidarestat on experimental diabetic neuropathy in the rat , 2006, Diabetologia.

[49]  H. Kamiya,et al.  Degeneration of the Golgi and neuronal loss in dorsal root ganglia in diabetic BioBreeding/Worcester rats , 2006, Diabetologia.

[50]  P. Low,et al.  Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury , 2006, Journal of the Neurological Sciences.

[51]  R. Pop-Busui,et al.  Diabetic neuropathy and oxidative stress , 2006, Diabetes/metabolism research and reviews.

[52]  R. Kawamori,et al.  Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy , 2006, Diabetes Care.

[53]  S. Chung,et al.  Aldose Reductase–Deficient Mice Are Protected From Delayed Motor Nerve Conduction Velocity, Increased c-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage , 2006, Diabetes.

[54]  Y. Sunada,et al.  VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice , 2006, The journal of gene medicine.

[55]  Lei Zhang,et al.  Gene Transfer of an Engineered Transcription Factor Promoting Expression of VEGF-A Protects Against Experimental Diabetic Neuropathy , 2006, Diabetes.

[56]  M. Stevens,et al.  Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. , 2006, Free radical biology & medicine.

[57]  R. Wada,et al.  Prolonged ischemic conduction failure after reperfusion in diabetic nerve , 2006, Muscle & nerve.

[58]  James Albers,et al.  Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. , 2006, Diabetes care.

[59]  C. Yabe-Nishimura,et al.  Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. , 2006, Journal of pharmacological sciences.

[60]  P. Hossain,et al.  Early detection of diabetic peripheral neuropathy with corneal confocal microscopy , 2005, The Lancet.

[61]  T. Sasase,et al.  Novel protein kinase C‐β isoform selective inhibitor JTT‐010 ameliorates both hyper‐ and hypoalgesia in streptozotocin‐ induced diabetic rats , 2005, Diabetes, obesity & metabolism.

[62]  M. Fujimiya,et al.  The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  A. Verkhratsky,et al.  Neurotrophin-3 prevents mitochondrial dysfunction in sensory neurons of streptozotocin-diabetic rats , 2005, Experimental Neurology.

[64]  R. Wada,et al.  Role of Advanced Glycation End Products and Their Receptors in Development of Diabetic Neuropathy , 2005, Annals of the New York Academy of Sciences.

[65]  M. Nangle,et al.  Inhibitors of Advanced Glycation End Product Formation and Neurovascular Dysfunction in Experimental Diabetes , 2005, Annals of the New York Academy of Sciences.

[66]  H. Sone,et al.  Vascular risk factors and diabetic neuropathy. , 2005, The New England journal of medicine.

[67]  E. Schleicher,et al.  The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). , 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[68]  S. Shaw,et al.  Aldose reductase pathway mediates JAK‐STAT signaling: a novel axis in myocardial ischemic injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  E. Feldman,et al.  Short‐term hyperglycemia produces oxidative damage and apoptosis in neurons , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  Dan Ziegler,et al.  Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.

[71]  D. Zochodne,et al.  Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? , 2005, Diabetes.

[72]  W. Köpcke,et al.  Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study). , 2005, International journal of clinical pharmacology and therapeutics.

[73]  C. Szabó,et al.  Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. , 2005, Diabetes.

[74]  P. K. Thomas,et al.  Sural nerve pathology in diabetic patients with minimal but progressive neuropathy , 2005, Diabetologia.

[75]  J. Schneider,et al.  Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. , 2004, The Journal of clinical investigation.

[76]  S. Yagihashi,et al.  Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. , 2004, Diabetes.

[77]  Fei Li,et al.  C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. , 2004, American journal of physiology. Endocrinology and metabolism.

[78]  S. Yagihashi,et al.  Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. , 2004, Biochemical and biophysical research communications.

[79]  Justin C McArthur,et al.  The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. , 2004, Brain : a journal of neurology.

[80]  Whei-Min Lin,et al.  Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. , 2004, Brain : a journal of neurology.

[81]  Fei Li,et al.  Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. , 2004, Diabetes.

[82]  R. Wada,et al.  Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine , 1996, Diabetologia.

[83]  M. Cotter,et al.  Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats , 1993, Diabetologia.

[84]  P. Thomas,et al.  Pattern of myelinated fibre loss in the sural nerve in neuropathy related to Type 1 (insulin-dependent) diabetes , 1988, Diabetologia.

[85]  P. K. Thomas,et al.  Abnormal innervation of lower limb epineurial arterioles in human diabetes , 2004, Diabetologia.

[86]  S. Yagihashi,et al.  Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice , 2003, Journal of neurochemistry.

[87]  K. Eriksson,et al.  Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. , 2003, Diabetes.

[88]  A. Vinik,et al.  Nerve Growth Factor and Diabetic Neuropathy , 2003, Experimental diabesity research.

[89]  R. Neubig,et al.  Diabetic neuropathy: inhibitory G protein dysfunction involves PKC‐dependent phosphorylation of Goα , 2003, Journal of neurochemistry.

[90]  N. Calcutt,et al.  Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. , 2003, Diabetes.

[91]  P. Fernyhough,et al.  Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. , 2003, Brain : a journal of neurology.

[92]  R. A. Malik,et al.  Corneal confocal microscopy: a non-invasive surrogate of nerve fibre damage and repair in diabetic patients , 2003, Diabetologia.

[93]  S. Yagihashi,et al.  The Possible Role of Tumor Necrosis Factor-α in Diabetic Polyneuropathy , 2003, Experimental diabesity research.

[94]  N. Hotta,et al.  Polyol pathway and protein kinase C activity of rat Schwannoma cells , 2003, Diabetes/metabolism research and reviews.

[95]  D. Wright,et al.  Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice , 2003, Experimental Neurology.

[96]  C. Sumner,et al.  The spectrum of neuropathy in diabetes and impaired glucose tolerance , 2003, Neurology.

[97]  A. Kashiwagi,et al.  Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKCdelta in diabetic rats. , 2003, Neuroreport.

[98]  R. Pop-Busui,et al.  Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. , 2002, Diabetes.

[99]  M. Cotter,et al.  Effects of protein kinase Cβ inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism , 2002, Diabetes/metabolism research and reviews.

[100]  E. Scarpini,et al.  Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1β and p75NTR , 2002, Journal of the Neurological Sciences.

[101]  P. McMorran,et al.  Aggravated reperfusion injury in STZ‐diabetic nerve , 2002, Journal of the peripheral nervous system : JPNS.

[102]  D. Greene,et al.  An aldose reductase inhibitor reverses early diabetes‐induced changes in peripheral nerve function, metabolism, and antioxidative defense , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[103]  Paul J Thornalley Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. , 2002, International review of neurobiology.

[104]  G. King,et al.  Protein kinase C and the development of diabetic vascular complications , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[105]  R. Wada,et al.  Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. , 2001, Brain : a journal of neurology.

[106]  S. Tripp,et al.  Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy , 2001, Neurology.

[107]  R. Wada,et al.  Effects of OPB‐9195, anti‐glycation agent, on experimental diabetic neuropathy , 2001, European journal of clinical investigation.

[108]  S. Yagihashi,et al.  Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients , 2001, Virchows Archiv.

[109]  R. Schmidt,et al.  Effect of NGF and Neurotrophin‐3 Treatment on Experimental Diabetic Autonomic Neuropathy , 2001, Journal of neuropathology and experimental neurology.

[110]  D. Greene,et al.  Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. , 2000, Diabetes.

[111]  H. Tritschler,et al.  Alpha-lipoic acid: effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy. , 1999, Diabetes.

[112]  A. Boulton,et al.  Structural abnormalities do not explain the early functional abnormalities in the peripheral nerves of the streptozotocin diabetic rat , 1999, Journal of anatomy.

[113]  N. Hotta,et al.  A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.

[114]  D. Tomlinson Mitogen-activated protein kinases as glucose transducers for diabetic complications , 1999, Diabetologia.

[115]  S. Apfel Neurotrophic factors in the therapy of diabetic neuropathy. , 1999, The American journal of medicine.

[116]  E. Feldman,et al.  Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. , 1999, European journal of pharmacology.

[117]  J. Riggs Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. , 1998, Neurology.

[118]  M. Cronin,et al.  Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor. , 1998, Diabetes.

[119]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[120]  W. Litchy,et al.  Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy , 1998, Neurology.

[121]  S. Yagihashi,et al.  Localization in human diabetic peripheral nerve of Nɛ-carboxymethyllysine-protein adducts, an advanced glycation endproduct , 1997, Diabetologia.

[122]  P. Fernyhough,et al.  Role of Neurotrophins in Diabetic Neuropathy and Treatment with Nerve Growth Factors , 1997, Diabetes.

[123]  M. Pfeifer,et al.  Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs? , 1997, Diabetes.

[124]  R. Wada,et al.  Effects of cilostazol on the peripheral nerve function and structure in STZ-induced diabetic rats. , 1997, Journal of diabetes and its complications.

[125]  M. Donaghy,et al.  Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus , 1997, Muscle & nerve.

[126]  S. Yagihashi,et al.  Effects of aminoguanidine on structural alterations of microvessels in peripheral nerve of streptozotocin diabetic rats. , 1997, Microvascular research.

[127]  E. Feldman,et al.  Pathogenesis of diabetic neuropathy. , 1989, Clinical neuroscience.

[128]  S. Yagihashi,et al.  Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. , 1997, Diabetologia.

[129]  P. Dyck,et al.  Pathologic Alterations in the Diabetic Neuropathies of Humans: A Review , 1996, Journal of neuropathology and experimental neurology.

[130]  G. Wendelschafer‐Crabb,et al.  Quantitation of epidermal nerves in diabetic neuropathy , 1996, Neurology.

[131]  D. Zochodne Neurotrophins and Other Growth Factors in Diabetic Neuropathy , 1996, Seminars in neurology.

[132]  G. Rosoklija,et al.  Diabetic peripheral neuropathy: A clinicopathologic and immunohistochemical analysis of sural nerve biopsies , 1996, Muscle & nerve.

[133]  P. Kopelman,et al.  The role of endogenous nerve growth factor in human diabetic neuropathy , 1996, Nature Medicine.

[134]  R. Wada,et al.  Galactosemic Neuropathy in Transgenic Mice for Human Aldose Reductase , 1996, Diabetes.

[135]  M. Hanefeld,et al.  Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). , 1995, Diabetologia.

[136]  J. McArthur,et al.  Cutaneous innervation in sensory neuropathies , 1995, Neurology.

[137]  S. Yagihashi,et al.  Pathology and pathogenetic mechanisms of diabetic neuropathy. , 1995, Diabetes/metabolism reviews.

[138]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[139]  N. Hotta,et al.  Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[140]  J. Arezzo,et al.  Nerve growth factor administration protects against experimental diabetic sensory neuropathy , 1994, Brain Research.

[141]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[142]  M. Cotter,et al.  Potential Therapeutic Approaches to the Treatment or Prevention of Diabetic Neuropathy: Evidence from Experimental Studies , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[143]  E. Feldman,et al.  Complications: Neuropathy, Pathogenetic Considerations , 1992, Diabetes Care.

[144]  C J Watkins,et al.  Innervation of the Vasa Nervorum: Changes in Human Diabetics , 1992, Journal of neuropathology and experimental neurology.

[145]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[146]  D. Greene,et al.  Endoneurial Microvessels in Human Diabetic Neuropathy: Endothelial Cell Dysjunction and Lack of Treatment Effect by Aldose Reductase Inhibitor , 1991, Diabetes.

[147]  P. Low,et al.  Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[148]  P. Low,et al.  Endoneurial blood flow in rat sciatic nerve during development. , 1991, The Journal of physiology.

[149]  R. Hellweg,et al.  Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy , 1990, Journal of neuroscience research.

[150]  J. Kinoshita,et al.  A thirty year journey in the polyol pathway. , 1990, Experimental eye research.

[151]  T. Vilén,et al.  Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. , 1988, The New England journal of medicine.

[152]  W W Monafo,et al.  Regional blood flow in sciatic nerve, biceps femoris muscle, and truncal skin in response to hemorrhagic hypotension. , 1987, The Journal of trauma.

[153]  D. Greene,et al.  Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.

[154]  P. Dyck,et al.  The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia , 1986, Annals of neurology.

[155]  P. Wagner Gas exchange in chronic pulmonary disease. , 1985, Clinical physiology.

[156]  J. Jakobsen,et al.  Nerve morphology in experimental diabetes , 1985, Clinical physiology.

[157]  P J Dyck,et al.  Spatial pattern of nerve fiber abnormality indicative of pathologic mechanism. , 1984, The American journal of pathology.

[158]  P. Dyck,et al.  Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry , 1980, Annals of neurology.

[159]  Clarke Bf,et al.  Prognosis in diabetic autonomic neuropathy. , 1980 .

[160]  D. Ewing,et al.  The natural history of diabetic autonomic neuropathy. , 1980, The Quarterly journal of medicine.

[161]  S. Yagihashi,et al.  Ultrastructural pathology of peripheral nerves in patients with diabetic neuropathy. , 1979, The Tohoku journal of experimental medicine.

[162]  J. Pirart Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 , 1978, Diabetes Care.

[163]  A. Kobrine,et al.  Absence of autoregulation in peripheral nerve blood flow , 1977, Journal of the Neurological Sciences.

[164]  D. Ewing,et al.  MORTALITY IN DIABETIC AUTONOMIC NEUROPATHY , 1976, The Lancet.

[165]  K. Gabbay,et al.  Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.